Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma
Sari F. Alhasan(Newcastle University), Helen L. Reeves(Newcastle upon Tyne Hospital), Anna Long(Royal Victoria Infirmary), Gary Beale(Newcastle University), Dina Tiniakos(National and Kapodistrian University of Athens), Richard Charnley(Newcastle upon Tyne Hospitals NHS Foundation Trust), Beate Haugk(Royal Victoria Infirmary), Alastair D. Burt(NIHR Newcastle Biomedical Research Centre), Laura Ogle(Newcastle University), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), David R. Newell(Newcastle University), Despina Televantou(Aristotle University of Thessaloniki)
Cited by 23
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Serum markers detect the presence of liver fibrosis: A cohort study
|Gastroenterology|2004|1.1k
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
Clinical and genetic characteristics of hereditary pancreatitis in Europe
|Clinical Gastroenterology and Hepatology|2004|615